{"success":true,"data":{"pressRelease":{"id":"145603","rtpr_id":"nBw15fBS0a-20260916","ticker":"ABCL","exchange":"NASDAQ","all_tickers":["ABCL"],"title":"AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026","author":"Business Wire","published_at":"2026-09-16T20:05:00.105Z","article_body":"AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World\nCongress on Menopause 2026\n\nAbCellera\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=AbCellera&index=1&md5=bcbd8743efc48a61c9d367ebf20c4319)\n(Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data\non ABCL635 at the International Menopause Society (IMS) 20th World Congress on\nMenopause, to be held September 30 to October 3, 2026 at the Windsor Oceânico\nHotel and Congress Center in Rio de Janeiro, Brazil.\n\nDetails on AbCellera’s oral presentation at IMS are as follows:\n\nTitle: Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R\nMonoclonal Antibody for the Treatment of Vasomotor Symptoms\n\nAbstract ID: 16836\n\nSession: Symptoms of Menopause 1\n\nDate and Time: Thursday, October 1 from 8:30 a.m. to 9:30 a.m. GMT-3\n\nLocation: Aruba 1, Windsor Oceânico Hotel and Congress Center\n\nAbCellera will present efficacy and safety data from its Phase 2 trial in\npostmenopausal women with moderate-to-severe vasomotor symptoms (VMS). The\nabstract can be viewed online here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimsrio2026.com%2Fscientific-program%2F&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=here&index=2&md5=2bf32bd1ab40022838779175c21bd28c)\n.\n\nAbout ABCL635\n\nABCL635 is a potential best-in-class investigational antibody drug for the\nnon-hormonal, long-acting treatment of moderate-to-severe VMS, commonly known\nas hot flashes, due to menopause. ABCL635 specifically targets NK3R, a\nclinically validated G protein-coupled receptor (GPCR) expressed on KNDy\nneurons in the infundibular nucleus of the hypothalamus. ABCL635 is\nAbCellera’s first pipeline program from the GPCR and ion channel platform to\nadvance into the clinic, in July 2025. Additional details are available at\nwww.abcellera.com/pipeline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com%2Fpipeline&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=www.abcellera.com%2Fpipeline&index=3&md5=d86401378b54ac61b35576d1a0e4afd1)\n.\n\nThe Phase 2 trial of ABCL635 (NCT07118891) is a multicenter, randomized,\ndouble-blind, placebo-controlled trial in postmenopausal women with\nmoderate-to-severe VMS due to menopause evaluating safety and efficacy of\nABCL635.\n\nAbout VMS\n\nHot flashes and night sweats, known as VMS, are the most common menopausal\nsymptoms, impacting up to 80% of women. The majority rate their VMS as\nmoderate to severe, characterized by intense feelings of heat that lead to\nsweating, chills, and interrupted sleep. VMS are the most frequent reason for\nseeking medical care for menopause. VMS can persist for many years after the\nfinal menstrual period, and the impact is felt across many aspects of everyday\nlife, including sleep, concentration, energy and mood, work, social\nactivities, and relationships. It is estimated that approximately 12 million\nwomen in the US experience moderate-to-severe VMS, of which more than six\nmillion seek treatment.\n\nAbout AbCellera Biologics Inc.\n\nAbCellera\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=AbCellera&index=4&md5=3b2f357c266a0c4cf68844370b657886)\n(Nasdaq: ABCL) is a clinical-stage biotechnology company focused on\ndiscovering and developing first-in-class antibody-based medicines in the\nareas of endocrinology, women’s health, immunology, oncology, and more. For\nmore information, please visit www.abcellera.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=www.abcellera.com&index=5&md5=13ed1b863a60e27fadb09fe9de29f730)\n.\n\nAbCellera Forward-looking Statements\n\nThis document contains forward-looking statements, including statements made\npursuant to the safe harbor provisions of the Private Securities Litigation\nReform Act of 1995. The forward-looking statements are based on management’s\nbeliefs and assumptions and on information currently available to management.\nAll statements contained in this document other than statements of historical\nfact are forward-looking statements, including statements regarding our\nability to develop, commercialize and achieve market acceptance of our current\nand planned products and services, our research and development efforts, and\nother matters regarding our business strategies, use of capital, results of\noperations and financial position, plans, objectives for future operations,\nand the evaluation of our available liquidity to execute on our strategy\n(including our ability to access our reimbursement based R&D government\ncontributions). The use of certain data derived from cross-study comparisons\nare not based on any head-to-head clinical trials. Cross-study comparisons are\ninherently limited and may suggest misleading similarities and differences and\nare presented for informational purposes. In some cases, you can identify\nforward-looking statements by the words “may,” “will,” “could,”\n“would,” “should,” “expect,” “intend,” “plan,”\n“anticipate,” “believe,” “estimate,” “predict,” “project,”\n“potential,” “continue,” “ongoing” or the negative of these terms\nor other comparable terminology, although not all forward-looking statements\ncontain these words.\n\nThese statements involve risks, uncertainties and other factors that may cause\nactual results, levels of activity, performance, or achievements to be\nmaterially different from the information expressed or implied by these\nforward-looking statements. These risks, uncertainties, other factors, and\ndefinition of our business metrics are described under “Risk Factors,”\n“Management’s Discussion and Analysis of Financial Condition and Results\nof Operations” and elsewhere in the documents we file with the Securities\nand Exchange Commission from time to time. We caution you that forward-looking\nstatements are based on a combination of facts and factors currently known by\nus and our projections of the future, about which we cannot be certain. As a\nresult, the forward-looking statements may not prove to be accurate. The\nforward-looking statements in this document represent our views as of the date\nhereof. We undertake no obligation to update any forward-looking statements\nfor any reason, except as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260916319324/en/\n(https://www.businesswire.com/news/home/20260916319324/en/)\n\nInquiries \n\nMedia: Tiffany Chiu; media@abcellera.com (mailto:media@abcellera.com) ,\n+1(236)521-6774\n\nPartnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com\n(mailto:partnering@abcellera.com) , +1(604)559-9005\n\nInvestor Relations: Peter Ahn; ir@abcellera.com (mailto:ir@abcellera.com) ,\n+1(778)729-9116\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw15fBS0a-20260916","title":"AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026","author":"Business Wire","ticker":"ABCL","created":"2026-09-16T20:05:00.105Z","tickers":["ABCL"],"exchange":"NASDAQ","article_body":"AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World\nCongress on Menopause 2026\n\nAbCellera\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=AbCellera&index=1&md5=bcbd8743efc48a61c9d367ebf20c4319)\n(Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data\non ABCL635 at the International Menopause Society (IMS) 20th World Congress on\nMenopause, to be held September 30 to October 3, 2026 at the Windsor Oceânico\nHotel and Congress Center in Rio de Janeiro, Brazil.\n\nDetails on AbCellera’s oral presentation at IMS are as follows:\n\nTitle: Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R\nMonoclonal Antibody for the Treatment of Vasomotor Symptoms\n\nAbstract ID: 16836\n\nSession: Symptoms of Menopause 1\n\nDate and Time: Thursday, October 1 from 8:30 a.m. to 9:30 a.m. GMT-3\n\nLocation: Aruba 1, Windsor Oceânico Hotel and Congress Center\n\nAbCellera will present efficacy and safety data from its Phase 2 trial in\npostmenopausal women with moderate-to-severe vasomotor symptoms (VMS). The\nabstract can be viewed online here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimsrio2026.com%2Fscientific-program%2F&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=here&index=2&md5=2bf32bd1ab40022838779175c21bd28c)\n.\n\nAbout ABCL635\n\nABCL635 is a potential best-in-class investigational antibody drug for the\nnon-hormonal, long-acting treatment of moderate-to-severe VMS, commonly known\nas hot flashes, due to menopause. ABCL635 specifically targets NK3R, a\nclinically validated G protein-coupled receptor (GPCR) expressed on KNDy\nneurons in the infundibular nucleus of the hypothalamus. ABCL635 is\nAbCellera’s first pipeline program from the GPCR and ion channel platform to\nadvance into the clinic, in July 2025. Additional details are available at\nwww.abcellera.com/pipeline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com%2Fpipeline&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=www.abcellera.com%2Fpipeline&index=3&md5=d86401378b54ac61b35576d1a0e4afd1)\n.\n\nThe Phase 2 trial of ABCL635 (NCT07118891) is a multicenter, randomized,\ndouble-blind, placebo-controlled trial in postmenopausal women with\nmoderate-to-severe VMS due to menopause evaluating safety and efficacy of\nABCL635.\n\nAbout VMS\n\nHot flashes and night sweats, known as VMS, are the most common menopausal\nsymptoms, impacting up to 80% of women. The majority rate their VMS as\nmoderate to severe, characterized by intense feelings of heat that lead to\nsweating, chills, and interrupted sleep. VMS are the most frequent reason for\nseeking medical care for menopause. VMS can persist for many years after the\nfinal menstrual period, and the impact is felt across many aspects of everyday\nlife, including sleep, concentration, energy and mood, work, social\nactivities, and relationships. It is estimated that approximately 12 million\nwomen in the US experience moderate-to-severe VMS, of which more than six\nmillion seek treatment.\n\nAbout AbCellera Biologics Inc.\n\nAbCellera\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=AbCellera&index=4&md5=3b2f357c266a0c4cf68844370b657886)\n(Nasdaq: ABCL) is a clinical-stage biotechnology company focused on\ndiscovering and developing first-in-class antibody-based medicines in the\nareas of endocrinology, women’s health, immunology, oncology, and more. For\nmore information, please visit www.abcellera.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54602403&newsitemid=20260916319324&lan=en-US&anchor=www.abcellera.com&index=5&md5=13ed1b863a60e27fadb09fe9de29f730)\n.\n\nAbCellera Forward-looking Statements\n\nThis document contains forward-looking statements, including statements made\npursuant to the safe harbor provisions of the Private Securities Litigation\nReform Act of 1995. The forward-looking statements are based on management’s\nbeliefs and assumptions and on information currently available to management.\nAll statements contained in this document other than statements of historical\nfact are forward-looking statements, including statements regarding our\nability to develop, commercialize and achieve market acceptance of our current\nand planned products and services, our research and development efforts, and\nother matters regarding our business strategies, use of capital, results of\noperations and financial position, plans, objectives for future operations,\nand the evaluation of our available liquidity to execute on our strategy\n(including our ability to access our reimbursement based R&D government\ncontributions). The use of certain data derived from cross-study comparisons\nare not based on any head-to-head clinical trials. Cross-study comparisons are\ninherently limited and may suggest misleading similarities and differences and\nare presented for informational purposes. In some cases, you can identify\nforward-looking statements by the words “may,” “will,” “could,”\n“would,” “should,” “expect,” “intend,” “plan,”\n“anticipate,” “believe,” “estimate,” “predict,” “project,”\n“potential,” “continue,” “ongoing” or the negative of these terms\nor other comparable terminology, although not all forward-looking statements\ncontain these words.\n\nThese statements involve risks, uncertainties and other factors that may cause\nactual results, levels of activity, performance, or achievements to be\nmaterially different from the information expressed or implied by these\nforward-looking statements. These risks, uncertainties, other factors, and\ndefinition of our business metrics are described under “Risk Factors,”\n“Management’s Discussion and Analysis of Financial Condition and Results\nof Operations” and elsewhere in the documents we file with the Securities\nand Exchange Commission from time to time. We caution you that forward-looking\nstatements are based on a combination of facts and factors currently known by\nus and our projections of the future, about which we cannot be certain. As a\nresult, the forward-looking statements may not prove to be accurate. The\nforward-looking statements in this document represent our views as of the date\nhereof. We undertake no obligation to update any forward-looking statements\nfor any reason, except as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260916319324/en/\n(https://www.businesswire.com/news/home/20260916319324/en/)\n\nInquiries \n\nMedia: Tiffany Chiu; media@abcellera.com (mailto:media@abcellera.com) ,\n+1(236)521-6774\n\nPartnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com\n(mailto:partnering@abcellera.com) , +1(604)559-9005\n\nInvestor Relations: Peter Ahn; ir@abcellera.com (mailto:ir@abcellera.com) ,\n+1(778)729-9116\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-16T20:05:00.164627392Z","server_sent_at_ms":1789589100164},"received_at":"2026-09-16T20:05:00.222Z","source_url":"https://www.businesswire.com/news/home/20260916319324/en/"},"analysis":{"id":"134442","press_release_id":"145603","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["No clinical data disclosed in this release; all Phase 2 efficacy and safety results are deferred to the October 1 oral presentation"],"eventType":"clinical_trial","narrative":"AbCellera will deliver an oral presentation of interim Phase 2 data for ABCL635 at the IMS 20th World Congress on Menopause in Rio de Janeiro, with the session scheduled for October 1, 2026.\n\nThe data come from a Phase 1/2 study of ABCL635, a first-in-class NK3R monoclonal antibody for the non-hormonal, long-acting treatment of moderate-to-severe vasomotor symptoms (hot flashes); the Phase 2 trial is a multicenter, randomized, double-blind, placebo-controlled study in postmenopausal women.\n\nABCL635 is AbCellera's first pipeline program from its GPCR and ion channel platform to reach the clinic, entering in July 2025, and the company estimates approximately 12 million US women experience moderate-to-severe VMS, of which more than six million seek treatment.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar the October 1 interim Phase 2 readout for ABCL635 — first disclosed clinical data from AbCellera's internal GPCR platform pipeline."},"keyFigures":{"drugName":"ABCL635","phaseOfTrial":"Phase 2 (interim results of a Phase 1/2 study)","customDimensions":{"nct_id":"NCT07118891","conference":"IMS 20th World Congress on Menopause, Rio de Janeiro, September 30 - October 3, 2026","abstract_id":"16836","vms_incidence":"up to 80% of women","presentation_date":"2026-10-01, 8:30-9:30 a.m. GMT-3","first_entered_clinic":"July 2025","us_women_seeking_treatment":"more than six million","us_women_with_moderate_to_severe_vms":"approximately 12 million"}},"namedEntities":{"people":[{"name":"Tiffany Chiu","role":"Media contact"},{"name":"Murray McCutcheon, Ph.D.","role":"Partnering contact"},{"name":"Peter Ahn","role":"Investor Relations"}],"products":["ABCL635"],"companies":[{"name":"AbCellera Biologics Inc.","ticker":"ABCL","relationship":"filer / issuer"},{"name":"International Menopause Society (IMS)","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"This is a conference scheduling announcement — no efficacy or safety data are disclosed. Its value is setting an interim Phase 2 readout date (October 1, 2026) for ABCL635, AbCellera's lead internal pipeline asset, making it a watchlist catalyst rather than market-moving news."},"tickerRelevance":{"others":[],"primary":"ABCL"},"globalImportance":22,"audienceRelevance":28,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","catalystDate":"2026-10-01","eventGravity":"conference presentation announcement, no data disclosed","sectorWeight":"women's health / endocrinology niche","issuerAuthored":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"AbCellera will deliver an oral presentation of interim Phase 2 data for ABCL635 at the IMS 20th World Congress on Menopause in Rio de Janeiro, with the session scheduled for October 1, 2026.\n\nThe data come from a Phase 1/2 study of ABCL635, a first-in-class NK3R monoclonal antibody for the non-hormonal, long-acting treatment of moderate-to-severe vasomotor symptoms (hot flashes); the Phase 2 trial is a multicenter, randomized, double-blind, placebo-controlled study in postmenopausal women.\n\nABCL635 is AbCellera's first pipeline program from its GPCR and ion channel platform to reach the clinic, entering in July 2025, and the company estimates approximately 12 million US women experience moderate-to-severe VMS, of which more than six million seek treatment.","key_figures":{"drugName":"ABCL635","phaseOfTrial":"Phase 2 (interim results of a Phase 1/2 study)","customDimensions":{"nct_id":"NCT07118891","conference":"IMS 20th World Congress on Menopause, Rio de Janeiro, September 30 - October 3, 2026","abstract_id":"16836","vms_incidence":"up to 80% of women","presentation_date":"2026-10-01, 8:30-9:30 a.m. GMT-3","first_entered_clinic":"July 2025","us_women_seeking_treatment":"more than six million","us_women_with_moderate_to_severe_vms":"approximately 12 million"}},"named_entities":{"people":[{"name":"Tiffany Chiu","role":"Media contact"},{"name":"Murray McCutcheon, Ph.D.","role":"Partnering contact"},{"name":"Peter Ahn","role":"Investor Relations"}],"products":["ABCL635"],"companies":[{"name":"AbCellera Biologics Inc.","ticker":"ABCL","relationship":"filer / issuer"},{"name":"International Menopause Society (IMS)","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T20:05:29.458Z","global_importance":22,"audience_relevance":28,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","catalystDate":"2026-10-01","eventGravity":"conference presentation announcement, no data disclosed","sectorWeight":"women's health / endocrinology niche","issuerAuthored":true}},"durationMs":29129,"modelName":"glm-5.3-flash"}}